Sugi Predict

Sugi Predict / Targets / LRP6

LRP6

Low-density lipoprotein receptor-related protein 6 · O75581 · LRP6 on Sugi Atlas →

135 patent compounds predicted against LRP6, 27 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL29470937) 0.81 13/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1502437) 0.64 11/20
SCHEMBL19460949 SCHEMBL19460949 0.63 11/20
SCHEMBL10879201 SCHEMBL10879201 0.47 7/20
SCHEMBL6439541 SCHEMBL6439541 0.36 4/20
SCHEMBL14745528 SCHEMBL14745528 0.34 3/20
SCHEMBL21577430 SCHEMBL21577430 0.46 2/20
SCHEMBL2979085 SCHEMBL2979085 0.46 2/20
SCHEMBL31273615 SCHEMBL31273615 0.44 2/20
SCHEMBL9352187 SCHEMBL9352187 0.43 2/20
SCHEMBL9356171 SCHEMBL9356171 0.43 2/20
SCHEMBL10606874 SCHEMBL10606874 0.40 2/20
SCHEMBL30966772 SCHEMBL30966772 0.40 2/20
SCHEMBL11738892 SCHEMBL11738892 0.39 2/20
SCHEMBL7122710 SCHEMBL7122710 0.39 2/20
SCHEMBL14741144 SCHEMBL14741144 0.38 2/20
SCHEMBL28608473 SCHEMBL28608473 0.36 2/20
SCHEMBL14745466 SCHEMBL14745466 0.36 2/20
SCHEMBL14535764 SCHEMBL14535764 0.35 2/20
SCHEMBL29546481 SCHEMBL29546481 0.35 2/20

Clinical trials — most relevant to LRP6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke PHASE4NOT_YET_RECRUITING
Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study PHASE4COMPLETED
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) PHASE3COMPLETED
Treatment of Severe Infection With Antihyperlipidemia Drug PHASE2/PHASE3UNKNOWN
Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like Nanoparticles PHASE2/PHASE3UNKNOWN
Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles PHASE2/PHASE3UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH PHASE1NOT_YET_RECRUITING
Klotho _ LRP-6 _ Gastric Adenocarcinoma nanUNKNOWN
LRP1 and Colon Cancer nanUNKNOWN
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury nanUNKNOWN
Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5 nanCOMPLETED
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids nanRECRUITING
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) nanWITHDRAWN
LRP1 Methylation and Colon Cancer nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1) nanCOMPLETED
Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt nanNOT_YET_RECRUITING
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia nanCOMPLETED
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED
Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia nanCOMPLETED
Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients nanUNKNOWN
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events nanCOMPLETED
Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile nanNOT_YET_RECRUITING
Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study nanUNKNOWN
Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers nanCOMPLETED
Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LRP6 binder may also engage these)

ProteinNameSimilarity
O88572 — 1.000 O88572 →
O75197 — 0.995 O75197 →
Q91VN0 — 0.995 Q91VN0 →
Q9QYP1 — 0.929 Q9QYP1 →
O75096 — 0.924 O75096 →
Q8VI56 — 0.924 Q8VI56 →
P55245 — 0.923 P55245 →
Q1EGL1 — 0.922 Q1EGL1 →
Q01279 — 0.922 Q01279 →
Q8N0V4 — 0.920 Q8N0V4 →
EGFR Epidermal growth factor receptor 0.919 landscape →
Q61526 — 0.918 Q61526 →
Q6H8D6 — 0.918 Q6H8D6 →
Q62799 — 0.917 Q62799 →
B5X3B2 — 0.917 B5X3B2 →
Q9C827 — 0.917 Q9C827 →
Q8K4Y5 — 0.916 Q8K4Y5 →
Q9CAA0 — 0.916 Q9CAA0 →
Q5VQ78 — 0.915 Q5VQ78 →
ACSL1 Long-chain-fatty-acid--CoA ligase 1 0.915 landscape →
ERBB3 Receptor tyrosine-protein kinase erbB-3 0.915 landscape →
Q6IS24 — 0.915 Q6IS24 →
Q6H8D5 — 0.915 Q6H8D5 →
NT5E 5'-nucleotidase 0.915 landscape →
Q5RB22 — 0.915 Q5RB22 →
Q9M8Y0 — 0.915 Q9M8Y0 →
Q3TIW9 — 0.915 Q3TIW9 →
Q05927 — 0.914 Q05927 →
Q8R4N0 — 0.914 Q8R4N0 →
Q08C93 — 0.914 Q08C93 →